Expand ARGX Menu
ARGX MENU

ARGX Latest Press Releases

-- March 20, 2026 --

argenx announces Annual General Meeting of Shareholders on May 6, 2026 Globe Newswire 4:01 PM

-- March 6, 2026 --

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline Globe Newswire 1:00 AM

-- February 26, 2026 --

argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update Globe Newswire 1:00 AM
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis Globe Newswire 12:30 AM

-- February 23, 2026 --

argenx to Present at TD Cowen 46th Annual Healthcare Conference Globe Newswire 1:00 AM

-- February 19, 2026 --

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026 Globe Newswire 1:00 AM

-- January 13, 2026 --

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG Globe Newswire 1:00 AM

-- January 12, 2026 --

argenx Highlights 2026 Strategic Priorities Globe Newswire 1:00 AM

-- January 6, 2026 --

argenx to Present at 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 1:00 AM

-- January 5, 2026 --

argenx Announces Leadership Transition Marking Next Evolution of Growth Globe Newswire 1:00 AM

-- December 15, 2025 --

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease Globe Newswire 1:00 AM

-- November 18, 2025 --

argenx Announces Results of Extraordinary General Meeting of Shareholders Globe Newswire 4:01 PM

-- October 30, 2025 --

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update Globe Newswire 2:00 AM

-- October 29, 2025 --

argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients Globe Newswire 11:00 AM
Market Data Delayed 15 Minutes